Global Heparin Anticoagulant Market Outlook 2021: Global Opportunity and Demand Analysis, Market Forecast, 2019-2028

The Global Heparin Anticoagulant Market is anticipated to rise at a value CAGR of 1.7% over 2019–2028. Heparin is an anticoagulant. It acts by preventing clotting in the blood caused by certain medical conditions or medical procedures. It is also used before surgery in treating cardiac disorders. It is used in the treatment of heart attacks and unstable angina. It is given either by the IV route or the subcutaneous route. Favourable government initiatives for better treatment have fueled the market further.

The high rate of occurrence of cardiovascular disorders has boosted the market
The rise in the incidences of Cardiac disorders has triggered the demand of the market; for instance, the Centre for Disease Control and Prevention has estimated that Coronary heart disease has caused the death of 365,914 people in the year 2017. The rise in the number of accidents and surgeries worldwide, an increase in the awareness regarding the use of heparin for anticoagulant effects, and an increase in the geriatric population have boosted the overall market.

Low Molecular Weight Heparin has dominated growth in the Global Heparin Anticoagulant Market
Based on the type, the 3D Heparin Anticoagulantsegment has held the highest segmental growth. As they efficiently prevent blood clots in the treatment of venous thromboembolism and also aid in the treatment of myocardial infarction. Low molecular weight heparin does not need anticoagulation monitoring and has a lower incidence of heparin-induced thrombocytopenia.
In terms of the route of administration, the subcutaneous route segment has held the largest growth in the market as it is preferred owing to ease of administration, and anticoagulants are required in small amounts due to the need for a reduced duration of treatment. Based on the application, the coronary artery disease segment has held the most significant growth owing to the rise in cases of CAD. Lifestyle habits like smoking and consumption of alcohol have further triggered the growth.
North America dominated the regional market with the increase in the incidence of cardiovascular disorders
The rise in the incidence of cardiovascular disorders like atrial fibrillation and coronary artery disease has significantly fueled the growth of North America. The availability of sophisticated healthcare infrastructure and the rise in healthcare expenditure have further been attributed to the regional growth of the market. The rise in sports activities in the region and a considerable rise in the injuries related to them have fueled the growth opportunities for the region. Furthermore, the increase in patient awareness has boosted the overall regional revenue.

Product launches, Innovations, Strategic Collaborations, Mergers, and Acquisition, are the major strategies of the competitors
The players in the global heparin anticoagulant market are fragmented. The key competitors in the Global Heparin Anticoagulant Market are GlaxoSmithKline plc; Pfizer, Inc; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; Teva Pharmaceutical Industries Ltd.; and Baxter.
GlaxoSmithKline plc: GlaxoSmithKline plc is one of the key competitors in the global heparin anticoagulant market. In January 2019, GlaxoSmithKline plc announced the acquisition of TESARO. They are an oncology-based company. This acquisition was made by GlaxoSmithKline to strengthen its product portfolio with oncology drugs. The deal for the acquisition was made for USD 5.1 billion.

Baxter is a popular competitor in the Global Heparin Anticoagulant Market. In December 2019, Baxter announced the acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi. The deal was made for USD 350 million. This acquisition was made by Baxter to expand its product portfolio.

Scope of the Report

By Type
• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Unfractionated Heparin

By Route of Administration
• Intravenous
• Subcutaneous

By Application
• Venous Thromboembolism
• Atrial Fibrillation
• Coronary Artery Disease
• Others

By Region
• North America
• Europe
• Asia Pacific
• Rest Of World

Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders a definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.